S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Ocular Therapeutix Stock Forecast, Price & News

-0.35 (-5.38%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
560,554 shs
Average Volume
1.01 million shs
Market Capitalization
$471.92 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Ocular Therapeutix logo

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.


Ocular Therapeutix (NASDAQ:OCUL) Sets New 1-Year Low at $6.53
November 18, 2021 |  americanbankingnews.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 6.9%
November 15, 2021 |  americanbankingnews.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $7.51
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$17.40 million
Book Value
$1.14 per share


Net Income
$-155.64 million
Net Margins
Pretax Margin




Free Float
Market Cap
$471.92 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.04 out of 5 stars

Medical Sector

572nd out of 1,388 stocks

Pharmaceutical Preparations Industry

267th out of 668 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix
or view top-rated stocks.

How has Ocular Therapeutix's stock price been impacted by Coronavirus (COVID-19)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCUL shares have increased by 15.1% and is now trading at $6.16.
View which stocks have been most impacted by COVID-19

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 4,030,000 shares, a decrease of 14.6% from the October 14th total of 4,720,000 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 5.3% of the shares of the company are sold short.
View Ocular Therapeutix's Short Interest

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Ocular Therapeutix

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.03. Ocular Therapeutix had a negative net margin of 229.02% and a negative trailing twelve-month return on equity of 22.95%. During the same period in the prior year, the company posted ($0.17) earnings per share.
View Ocular Therapeutix's earnings history

What price target have analysts set for OCUL?

5 brokerages have issued 1 year price objectives for Ocular Therapeutix's stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate Ocular Therapeutix's stock price to reach $24.00 in the next year. This suggests a possible upside of 289.6% from the stock's current price.
View analysts' price targets for Ocular Therapeutix
or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Antony Mattessich, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Donald Notman, Chief Financial Officer
  • Peter Jarrett, Chief Scientific Officer
  • Michael H. Goldstein, Chief Medical Officer & Ophthalmology President
  • Rabia Gurses Ozden, Senior Vice President-Clinical Development

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.49%), Deltec Asset Management LLC (2.81%), Geode Capital Management LLC (1.71%), Two Sigma Advisers LP (1.40%), Two Sigma Investments LP (1.17%) and Emerald Advisers LLC (1.11%). Company insiders that own Ocular Therapeutix stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends for Ocular Therapeutix

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Emerald Mutual Fund Advisers Trust, Altshuler Shaham Ltd, Emerald Advisers LLC, UBS Group AG, Goldman Sachs Group Inc., Two Sigma Investments LP, and Two Sigma Advisers LP.
View insider buying and selling activity for Ocular Therapeutix
or view top insider-selling stocks.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was bought by a variety of institutional investors in the last quarter, including Affinity Asset Advisors LLC, Cetera Investment Advisers, Altium Capital Management LP, Millennium Management LLC, Healthcare of Ontario Pension Plan Trust Fund, Morgan Stanley, Kornitzer Capital Management Inc. KS, and Tudor Investment Corp Et Al. Company insiders that have bought Ocular Therapeutix stock in the last two years include Antony C Mattessich, Opaleye Management Inc, and Summer Road Llc.
View insider buying and selling activity for Ocular Therapeutix
or or view top insider-buying stocks.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $6.16.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $471.92 million and generates $17.40 million in revenue each year. The biopharmaceutical company earns $-155.64 million in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 181 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at [email protected], or via fax at 781-357-4001.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.